These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2275292)

  • 21. NCCN Guideline update: Breast Cancer Version 1.2004.
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw; 2004 May; 2(3):183-4. PubMed ID: 19795602
    [No Abstract]   [Full Text] [Related]  

  • 22. [Which estrogens and gestagens should be prescribed after 45 years of age and for how long?].
    Göretzlehner G
    Zentralbl Gynakol; 1990; 112(13):793-4. PubMed ID: 2238980
    [No Abstract]   [Full Text] [Related]  

  • 23. [Recommendations for replacement of estrogens and progestins in climacteric and in postmenopause. 25. Arbeitstreffen des "Zürcher Gesprächskreises", November 2000].
    Birkhäuser M; Braendle W; Breckwoldt M; Keller PJ; Kuhl H; Runnebaum B
    Gynakol Geburtshilfliche Rundsch; 2001; 41(1):12-5. PubMed ID: 11423732
    [No Abstract]   [Full Text] [Related]  

  • 24. Hormone replacement therapy for women after breast carcinoma.
    Sands R; Studd J
    Curr Opin Obstet Gynecol; 1996 Jun; 8(3):216-20. PubMed ID: 8818533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone replacement therapy and estrogen-dependent cancers.
    Birkhäuser M
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal therapy with tamoxifen in male breast cancer.
    Hortobagyi GN; DiStefano A; Legha SS; Buzdar AU; Blumenschein GR
    Cancer Treat Rep; 1979 Apr; 63(4):539-41. PubMed ID: 221118
    [No Abstract]   [Full Text] [Related]  

  • 27. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gestagen supplementation to estrogen therapy in climacteric].
    Iversen OE
    Tidsskr Nor Laegeforen; 2001 Jan; 121(1):82-3. PubMed ID: 12013622
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hormone substitution in climacteric and postmenopause. Consensus report of the Austrian Menopause Society].
    Metka M; Heytmanek G; Enzelsberger H; Kurz C; Huber J; Brandstätter N; Tscherne G; Tabarelli M; Holzer G
    Wien Med Wochenschr; 1992; 142(5-6):94-5. PubMed ID: 1615684
    [No Abstract]   [Full Text] [Related]  

  • 30. The management of menopausal symptoms in women with breast cancer.
    Jubelirer SJ
    W V Med J; 1995 Feb; 91(2):54-6. PubMed ID: 7610643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 32. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
    Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adjuvant therapy also in node-negative breast cancer?].
    Barth JA
    Zentralbl Gynakol; 1990; 112(2):57-9. PubMed ID: 2316296
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast cancer--a medical disease?
    Crowell EB
    W V Med J; 1993 Oct; 89(10):448-51. PubMed ID: 8266683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study.
    Obi N; Chang-Claude J; Berger J; Braendle W; Slanger T; Schmidt M; Steindorf K; Ahrens W; Flesch-Janys D
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2207-13. PubMed ID: 19661079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Estrogen/progesterone substitution in and following menopause. Position of the German Society of Endocrinology].
    Ziegler R
    Med Monatsschr Pharm; 1989 Mar; 12(3):91-3. PubMed ID: 2704329
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
    Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
    Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone therapy and breast cancer risk.
    Foidart JM; Desreux J; Pintiaux A; Gompel A
    Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.